Peripheral Neuropathic Pain Pipeline Analysis Report 2025

Peripheral neuropathic pain is a chronic condition resulting from damage to peripheral nerves, often associated with diabetes, infections, or traumatic injuries. It accounts for a significant portion of global pain disorders, with around 50% of diabetics suffering from diabetic peripheral neuropathy. According to the peripheral neuropathic pain pipeline analysis by the publisher, the pipeline is witnessing a surge in targeted therapeutics and novel drug development. Increasing R&D investments, advancements in pain management therapies, and a growing focus on non-opioid alternatives are expected to drive significant pipeline growth in the coming years.

Report Coverage

The Peripheral Neuropathic Pain Pipeline Analysis Report by the publisher gives comprehensive insights into peripheral neuropathic pain therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for peripheral neuropathic pain. The peripheral neuropathic pain report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The peripheral neuropathic pain pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with peripheral neuropathic pain treatment guidelines to ensure optimal care practices.

The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to peripheral neuropathic pain.

Peripheral Neuropathic Pain Pipeline Outlook

Peripheral neuropathic pain is a chronic condition caused by damage or dysfunction in the peripheral nervous system. It often results from diabetes, infections, trauma, or toxins and leads to burning, tingling, or shooting pain. This occurs when damaged nerves send faulty pain signals to the brain, even without an actual injury or stimulus.

Peripheral neuropathic pain is treated using anticonvulsants, antidepressants, topical agents, and non-opioid analgesics to reduce nerve pain and improve quality of life. In January 2025, Vertex Pharmaceuticals advanced suzetrigine (Journavx) in its pipeline for peripheral neuropathic pain, including painful diabetic peripheral neuropathy, with ongoing Phase 3 trials evaluating its efficacy and safety.

Peripheral Neuropathic Pain Epidemiology

An epidemiological study published in 2024 reported a 14.6% overall prevalence of peripheral neuropathic pain (PN). Prevalence increased with age, peaking at 18.9% among individuals aged 61-65 years. Female subjects showed a higher rate (15.9%) compared to males (13.0%). Obesity was also linked to elevated prevalence (16.0%). The mean age of PN patients was 54.3 years, and the mean body mass index (BMI) was 27.5 kg/m².

Peripheral Neuropathic Pain - Pipeline Therapeutic Assessment

This section of the report covers the analysis of peripheral neuropathic pain drug candidates based on several segmentations, including:

By Phase

• Late-Stage Products (Phase 3 and Phase 4)
• Mid-Stage Products (Phase 2)
• Early-Stage Products (Phase I)
• Preclinical and Discovery Stage Products

By Drug Class

• Small Molecules
• Biologics
• Gene Therapies
• Peptides
• RNA-based Therapies
• Others

By Route of Administration

• Oral
• Parenteral
• Others

Peripheral Neuropathic Pain Pipeline Assessment Segmentation, By Phases

The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to analysis, phase II covers a major share of the total peripheral neuropathic pain clinical trials, with 41.94%, showing strong clinical focus and innovation. The other phases include phase III at 21.77%, phase IV at 16.94%, phase I at 14.52%, and early phase I at 4.84%. This robust pipeline, especially in later stages, indicates significant progress that could enhance treatment options in the peripheral neuropathic pain management.

Peripheral Neuropathic Pain Pipeline Assessment Segmentation, By Drug Classes

The drug molecule categories covered under the peripheral neuropathic pain pipeline analysis include small molecules, biologics, gene therapies, peptides, RNA-based therapies, and others. The peripheral neuropathic pain report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for peripheral neuropathic pain.

Fatty acid binding protein (FABP) inhibitors are emerging as a novel drug class in the peripheral neuropathic pain pipeline. For instance, ART26.12, a selective fatty acid binding protein (FABP) inhibitor developed by Artelo Biosciences, is progressing through Phase 1 clinical trials. This non-opioid candidate targets chemotherapy-induced peripheral neuropathy by modulating the endocannabinoid system, offering a potential alternative to conventional pain therapies.

Peripheral Neuropathic Pain Clinical Trials - Key Players

The report for the peripheral neuropathic pain pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed peripheral neuropathic pain therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in peripheral neuropathic pain clinical trials:

• GlaxoSmithKline
• Vertex Pharmaceuticals Incorporated
• Zhejiang Hanmai Pharmaceutical Technology Co., Ltd.
• Shanghai Jemincare Pharmaceutical Co., Ltd.
• Eli Lilly and Company
• Eurofarma Laboratorios S.A.
• Lexicon Pharmaceuticals
• Syqe Medical
• Merz Therapeutics GmbH
• Haisco Pharmaceutical Group Co., Ltd.

Peripheral Neuropathic Pain - Emerging Drugs Profile

This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for peripheral neuropathic pain. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of peripheral neuropathic pain drug candidates.

Drug: VX-993

VX-993, sponsored by Vertex Pharmaceuticals Incorporated, is being evaluated in a Phase II trial for its efficacy, safety, and tolerability in treating pain associated with diabetic peripheral neuropathy. The study aims to examine dose response and compare VX-993 with pregabalin and placebo. VX-993 is a selective NaV1.8 inhibitor targeting peripheral pain signaling without opioid-related risks.

GSK3858279

GSK3858279 is currently being evaluated in a Phase 2 clinical trial for diabetic peripheral neuropathic pain. Developed by GlaxoSmithKline, this monoclonal antibody targets the CCL17 protein, aiming to interrupt pain signaling pathways. The study is assessing its efficacy in pain reduction, while also examining safety, tolerability, pharmacokinetics, and target engagement in adults with chronic DPNP.

Key Questions Answered in the Peripheral Neuropathic Pain Pipeline Analysis Report

• Which companies/institutions are leading the peripheral neuropathic pain drug development?
• What is the efficacy and safety profile of peripheral neuropathic pain pipeline drugs?
• Which company is leading the peripheral neuropathic pain pipeline development activities?
• What is the current peripheral neuropathic pain commercial assessment?
• What are the opportunities and challenges present in the peripheral neuropathic pain pipeline landscape?
• What is the efficacy and safety profile of peripheral neuropathic pain pipeline drugs?
• Which company is conducting major trials for peripheral neuropathic pain drugs?
• Which companies/institutions are involved in peripheral neuropathic pain collaborations aimed at providing enhanced therapeutic alternatives for patients?
• What are the geographies covered for clinical trials in peripheral neuropathic pain?

Reasons To Buy This Report

The Peripheral Neuropathic Pain Pipeline Analysis Report provides a strategic overview of the latest and future landscape of treatments for peripheral neuropathic pain. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into peripheral neuropathic pain collaborations, regulatory environments, and potential growth opportunities.

This product will be delivered within 3-5 business days.